In a report released yesterday, Allen Klee from Maxim Group reiterated a Buy rating on Marpai (MRAI – Research Report), with a price target of $2.50. The company’s shares closed last Friday at $0.88, close to its 52-week low of $0.74.
According to TipRanks.com, Klee ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.5% and a 20.5% success rate. Klee covers the Technology sector, focusing on stocks such as CareCloud, Inc., Iveda Solutions, and Mitek Systems.
Currently, the analyst consensus on Marpai is a Moderate Buy with an average price target of $2.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on Marpai’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.22 million and GAAP net loss of $5.49 million. In comparison, last year the company had a GAAP net loss of $1.59 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MRAI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marpai Inc operates as a health plan company. It offers a health plan services system that addresses the problems of healthcare past and enables companies to provide healthcare to employees.
Read More on MRAI:
